NRIX - Nurix Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Francisco,
United States
Type: Equity
NRIX price evolution
NRIX
| (in millions $) | 1 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $117.69 | $50.71 | $55.53 | |
| Short term investments | $326.35 | $194.18 | $233.28 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $456.04 | $450.22 | $250.97 | $295.5 |
| Long term investments | $9.38 | $10.29 | $7.42 | |
| Property, plant & equipment | $44.15 | $47.39 | $47.17 | $47.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.81 | $61.7 | $60.09 | |
| Total investments | $335.73 | $204.47 | $240.7 | |
| Total assets | $513.6 | $511.03 | $312.67 | $355.6 |
| Current liabilities | ||||
| Accounts payable | $3.92 | $2.81 | $5.92 | $6.4 |
| Deferred revenue | $85.44 | $80.53 | $93.12 | |
| Short long term debt | $7.93 | $7.31 | $7.49 | |
| Total current liabilities | $86.3 | $80.78 | $87.62 | $86.96 |
| Long term debt | $20.89 | $21.85 | $23.13 | |
| Total noncurrent liabilities | $59.56 | $56.3 | $68.15 | |
| Total debt | $28.82 | $29.16 | $30.61 | |
| Total liabilities | $136.74 | $140.34 | $143.93 | $155.1 |
| Shareholders' equity | ||||
| Retained earnings | -$680.22 | -$631.26 | -$586.72 | -$545.2 |
| Other shareholder equity | $0.34 | -$0.14 | -$0.35 | -$0.66 |
| Total shareholder equity | $370.69 | $168.75 | $200.49 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $55.53 | $65.38 | $80.79 | $119.53 |
| Short term investments | $233.28 | $244.67 | $215.21 | $161.79 |
| Net receivables | $6 | $3.85 | ||
| Inventory | ||||
| Total current assets | $295.5 | $318.45 | $311.12 | $298.43 |
| Long term investments | $7.42 | $63.88 | $137.19 | $90.89 |
| Property, plant & equipment | $47.95 | $29.51 | $25.34 | $6.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.09 | $98.31 | $165.65 | $97.91 |
| Total investments | $240.7 | $308.55 | $352.4 | $252.68 |
| Total assets | $355.6 | $416.76 | $476.77 | $396.34 |
| Current liabilities | ||||
| Accounts payable | $6.4 | $5.06 | $6.65 | $3.41 |
| Deferred revenue | $93.12 | $73.61 | $100.23 | $93.48 |
| Short long term debt | $7.49 | $5.53 | $3.85 | |
| Total current liabilities | $86.96 | $70.66 | $66.26 | $44.54 |
| Long term debt | $23.13 | $6.43 | $9.19 | |
| Total noncurrent liabilities | $68.15 | $42.41 | $68.21 | $61.53 |
| Total debt | $30.61 | $11.96 | $13.04 | |
| Total liabilities | $155.1 | $113.06 | $134.47 | $106.07 |
| Shareholders' equity | ||||
| Retained earnings | -$545.2 | -$401.25 | -$220.89 | -$103.7 |
| Other shareholder equity | -$0.66 | -$4.32 | -$0.61 | $0.09 |
| Total shareholder equity | $200.49 | $303.7 | $342.3 | $290.27 |
| (in millions $) | 1 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.59 | $12.09 | $16.59 | $15.16 |
| Cost of revenue | ||||
| Gross Profit | $12.09 | $16.59 | $15.16 | |
| Operating activities | ||||
| Research & development | $48.92 | $50.01 | $49.71 | |
| Selling, general & administrative | $11.71 | $11.8 | $10.78 | |
| Total operating expenses | $67.2 | $60.63 | $61.8 | $60.49 |
| Operating income | -$48.54 | -$45.22 | -$45.33 | |
| Income from continuing operations | ||||
| EBIT | -$44.46 | -$41.43 | -$41.96 | |
| Income tax expense | $0.08 | $0.09 | $0.09 | |
| Interest expense | $5.74 | |||
| Net income | ||||
| Net income | -$48.96 | -$44.55 | -$41.52 | -$41.96 |
| Income (for common shares) | -$44.55 | -$41.52 | -$41.96 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $76.99 | $38.63 | $29.75 | $17.82 |
| Cost of revenue | ||||
| Gross Profit | $76.99 | $38.63 | $29.75 | $17.82 |
| Operating activities | ||||
| Research & development | $189.15 | $184.5 | $116.43 | $66.49 |
| Selling, general & administrative | $42.9 | $38 | $31.2 | $16.31 |
| Total operating expenses | $232.05 | $222.49 | $147.64 | $82.8 |
| Operating income | -$155.06 | -$183.87 | -$117.89 | -$64.98 |
| Income from continuing operations | ||||
| EBIT | -$143.95 | -$180.36 | -$117.06 | -$63.78 |
| Income tax expense | $0.13 | -$20.54 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$143.95 | -$180.36 | -$117.19 | -$43.24 |
| Income (for common shares) | -$143.95 | -$180.36 | -$117.19 | -$43.24 |
| (in millions $) | 1 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$44.55 | -$41.52 | -$41.96 | |
| Operating activities | ||||
| Depreciation | $4.09 | $3.89 | $3.76 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.85 | $7.82 | $8.02 | |
| Total cash flows from operations | -$39.7 | -$41.95 | $26.69 | |
| Investing activities | ||||
| Capital expenditures | -$1.94 | -$2.88 | -$2.58 | |
| Investments | -$129.13 | $38.4 | -$11.79 | |
| Total cash flows from investing | -$116.9 | -$131.07 | $35.51 | -$14.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $237.75 | $1.62 | $0.01 | |
| Net borrowings | ||||
| Total cash flows from financing | $285.15 | $237.75 | $1.62 | $0.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $44.42 | $66.98 | -$4.81 | $12.32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$143.95 | -$180.36 | -$117.19 | -$43.24 |
| Operating activities | ||||
| Depreciation | $13.65 | $10.81 | $6.08 | $2.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $33.67 | $28.13 | $15.8 | $4.3 |
| Total cash flows from operations | -$81.36 | -$159.81 | -$84.36 | -$0.08 |
| Investing activities | ||||
| Capital expenditures | -$8.4 | -$12.24 | -$5.66 | -$4.55 |
| Investments | $76.7 | $39.44 | -$102.59 | -$249.85 |
| Total cash flows from investing | $68.3 | $27.2 | -$108.25 | -$254.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.22 | $117.19 | $153.88 | $219.11 |
| Net borrowings | ||||
| Total cash flows from financing | $3.22 | $117.19 | $153.88 | $339.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.85 | -$15.42 | -$38.73 | $84.54 |
News
Fundamentals
| Market cap | $1.46B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 67.08M |
| Revenue | $56.42M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$176.98M |
| Revenue Q/Q | -31.84% |
| Revenue Y/Y | -17.76% |
| P/E ratio | -8.27 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 25.94 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.64 |
|---|---|
| ROA | -41.82% |
| ROE | N/A |
| Debt/Equity | 0.77 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.28 |
| Quick ratio | N/A |